Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer
Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years. Liquid biopsy markers have great potential to improve current diagnostic and prognostic methods. Here, we compared miRNAs and DNA methylation in matched plasma, wh...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
04 April 2023
|
| In: |
Scientific reports
Year: 2023, Jahrgang: 13, Pages: 1-9 |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-023-32243-x |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41598-023-32243-x Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41598-023-32243-x 
|
| Verfasserangaben: | Aoife Ward Gahlawat, Tania Witte, Peter Sinn & Sarah Schott |
| Zusammenfassung: | Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years. Liquid biopsy markers have great potential to improve current diagnostic and prognostic methods. Here, we compared miRNAs and DNA methylation in matched plasma, whole blood and tissues as a surrogate marker for OC. We found that while both cfDNA and cf-miRNAs levels were upregulated in OC compared to patients with benign lesions or healthy controls, only cf-miRNA levels were an independent prognosticator of survival. Following on our previous work, we found members of the miR-200 family, miR-200c and miR-141 to be upregulated in both plasma and matched tissues of OC patients which correlated with adverse clinical features. We could also show that the upregulation of miR-200c and -141 correlated with promoter DNA hypomethylation in tissues, but not in plasma or matched whole blood samples. As cf-miRNAs are more easily obtained and very stable in blood, we conclude that they might serve as a more appropriate surrogate liquid biopsy marker than cfDNA for OC. |
|---|---|
| Beschreibung: | Gesehen am 19.06.2023 |
| Beschreibung: | Online Resource |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-023-32243-x |